Cargando…
埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析
BACKGROUND AND OBJECTIVE: Targeted therapy has become an indispensable therapy method in advanced non-small cell lung cancer (NSCLC) treatment. Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can significantly prolong the survival of patients harboring EGFR gene mutation. Ic...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999815/ https://www.ncbi.nlm.nih.gov/pubmed/27118647 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.04.04 |